Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
Year: 2014
Type: article
Abstract: OBJECTIVE: Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status. RESEARCH DESIGN AND METHODS: A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years. RESULTS: Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved β-cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from 13 ± 0.5 to 38 ± 2.5 μg/mL (P < 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P < 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P < 0.005) and insulin secretion/insulin resistance index (r = 0.306, P < 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group. CONCLUSIONS: Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin.
Source: Diabetes Care
DOI: 10.2337/dc13-1745
Institutions: Audie L. Murphy Memorial VA Hospital, Texas Diabetes Institute, South Texas Veterans Health Care System, Georgetown University, Phoenix VA Health Care System, Arizona State University, State University of New York, SUNY Downstate Health Sciences University, Pennington Biomedical Research Center, Louisiana State University, University of Southern California, The University of Texas at San Antonio Health Science Center, Istituto di Fisiologia Clinica, University of California San Diego, VA San Diego Healthcare System, University of Tennessee Health Science Center, MedStar Health Research Institute
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Sanofi, Takeda Pharmaceuticals North America, University of Southern California, Novo Nordisk, National Institutes of Health, Health Science Center, University of Tennessee, Allergan, University of Texas Health Science Center at San Antonio, National Center for Advancing Translational Sciences
OpenAlex ID: W2063119849
